Bedside Snapshot

Use It For: CKD anemia (dialysis or not); chemotherapy anemia when treatment is not curative; zidovudine anemia in HIV; transfusion sparing in elective noncardiac, nonvascular surgery (Hb >10 to ≤13 g/dL, high blood loss expected)
Adult Dose: CKD off dialysis: 50 units/kg subcut 1–2×/week (KDIGO); differs from FDA label: 50–100 units/kg 3×/week
CKD on dialysis: 50–100 units/kg 3×/week (KDIGO, label)
Chemotherapy: 40,000 units subcut weekly (max 60,000/week)
Pediatric Dose: CKD (1 month and older): 50 units/kg 3×/week IV or subcut. Chemotherapy anemia (5–18 yr): 600 units/kg IV weekly (max 60,000 units). Neonates and infants: single-dose vials only
Onset / Duration: Reticulocytes rise within 10 days; Hb rise in 2–6 weeks. Never for acute anemia
Do Not Give / Hold If: Uncontrolled hypertension; PRCA; ESA allergy; multidose vials in neonates, infants, pregnancy, lactation
Hold for hard-to-control BP; keep Hb below 11.5 g/dL (KDIGO). Differs from FDA label: 11 g/dL on dialysis, 10 off
Watch For: Thrombosis (access clotting, DVT or PE, stroke, MI); BP surge with headache, confusion or seizure; PRCA (sudden severe anemia, low reticulocytes); anaphylaxis or blistering rash
Reversal / Rescue: No antidote: stop or reduce the dose; phlebotomy if Hb overshoots; treat hypertension and thrombosis; transfuse for acute or symptomatic anemia
Must Remember: Lowest dose that avoids transfusion, never a normal Hb: higher targets raised death, MI, stroke and access thrombosis. Check iron and bleeding before calling it a failure

Indications

ED / ICU / Transport

Continuing an established regimen: CKD or chemotherapy patients admitted on an ESA? Confirm the indication, the last dose, the Hb trend and who manages it before you reorder.
Not for acute anemia: Hemorrhage and any anemia that needs immediate correction are not its job, so transfuse instead.
Anemia of critical illness: Off-label, and not recommended. The EPO-3 ICU trial (n=1,460) found epoetin 40,000 units weekly did not reduce transfusions. It increased thrombotic events, with no significant mortality benefit.
Who may give it: Scheduled, ordered therapy. An RN gives it in dialysis, oncology, ICU or an infusion center. It is not an EMS medication. In transport, continue a home or interfacility regimen only on the sending order. Varies by state, agency and facility protocol.

Other Uses

Anemia of chronic kidney disease (CKD): Dialysis or not. The goal is fewer transfusions, once iron deficiency and other causes are corrected.
Chemotherapy-induced anemia: non-myeloid cancer, at least 2 more months of myelosuppressive chemotherapy planned, treatment not aimed at cure
Zidovudine-related anemia in HIV: zidovudine 4,200 mg/week or less and endogenous erythropoietin 500 mUnits/mL or less
Elective noncardiac, nonvascular surgery: Hb >10 to ≤13 g/dL with high expected blood loss; not for patients willing to donate autologous blood (label)
Selected myelodysplastic syndromes: hematology-directed (off-label)
Not indicated (FDA label): cancer without myelosuppressive chemotherapy or with curative intent; cardiac or vascular surgery (excess deaths after CABG); fatigue or quality of life

Dosing & Administration

Available Forms

Single-dose vials (preservative-free): 2,000, 3,000, 4,000 and 10,000 units/mL (Epogen, Procrit, Retacrit); 40,000 units/mL (Procrit, Retacrit)
Multiple-dose vials (benzyl alcohol): 20,000 units in 2 mL and 20,000 units/mL; contraindicated in neonates, infants, pregnancy and lactation
Excipients: Epogen and Procrit contain human albumin. Retacrit is albumin-free. EMS does not carry these.

Adult Dosing

Indication	Dose & Route	Repeat / Max	Notes
CKD not on dialysis	50 units/kg subcut 1–2×/week, or up to 100 units/kg every 2 weeks (KDIGO 2026, Table 7). Differs from FDA label: 50–100 units/kg 3×/week IV or subcut	KDIGO: change the dose or interval no more often than every 4 weeks; no fixed max	Start at Hb 8.5–10 g/dL for most people (KDIGO Rec 3.2.2 rationale; the recommendation itself gives no number); individualize. Label: consider starting when Hb <10 g/dL. Often rounded to 4,000 or 10,000 units. Hb rules: see Hold / Reassess
CKD on dialysis	50–100 units/kg 3×/week IV or subcut (KDIGO Table 7; same as label); the label recommends IV on hemodialysis (KDIGO leaves the route to preference, local practice and cost)	If Hb rises <1 g/dL after 4 weeks, increase 25 units/kg per dose (KDIGO; label: 25%), no more often than every 4 weeks; no fixed max (no added response above 300 units/kg 3×/week on hemodialysis)	Start at Hb 9–10 g/dL (KDIGO Rec 3.2.1). Differs from FDA label: start when Hb <10 g/dL. Hb rules: see Hold / Reassess
Chemotherapy-induced anemia	40,000 units subcut weekly, or 150 units/kg subcut 3×/week	After 4 weeks, if Hb rise <1 g/dL and Hb <10 g/dL: 60,000 units weekly or 300 units/kg 3×/week (max)	Start only if Hb <10 g/dL with at least 2 months of chemotherapy left. Reduce 25% if Hb rises >1 g/dL in any 2 weeks or reaches the level that avoids transfusion; withhold above it and restart 25% lower when needed. Stop at 8 weeks without response, or when chemotherapy ends
Zidovudine-related anemia (HIV)	100 units/kg IV or subcut 3×/week	If no Hb rise after 8 weeks, add 50–100 units/kg every 4–8 weeks; max 300 units/kg 3×/week	Withhold if Hb >12 g/dL; resume 25% lower when Hb <11 g/dL. Stop if no response after 8 weeks at 300 units/kg
Elective surgery (transfusion sparing)	300 units/kg subcut daily for 15 days (10 days before, day of, 4 days after), or 600 units/kg subcut weekly ×4 (21, 14 and 7 days before and day of surgery)	Max 15 daily doses or 4 weekly doses	Hb >10 to ≤13 g/dL. DVT prophylaxis recommended. Not for cardiac or vascular surgery

Pediatric Dosing

Indication	Dose (per kg) & Route	Max Single / Max Total	Notes
CKD (1 month and older)	50 units/kg 3×/week IV or subcut	Titrate as for adults (25% steps, no more often than every 4 weeks); no fixed max	Start when Hb <10 g/dL. Reduce or interrupt as Hb approaches or exceeds 12 g/dL
Chemotherapy-induced anemia (5–18 yr)	600 units/kg IV weekly	After 4 weeks, if Hb rise <1 g/dL and Hb still <10 g/dL: 900 units/kg IV weekly (max 60,000 units)	Not established under 5 years. Same start, dose-reduction, hold and stop rules as adults
Zidovudine-related anemia (HIV)	Not labeled for children: specialist use (published 50–400 units/kg 2–3×/week)	Per infectious disease or hematology specialist	Published experience only
Neonates (<1 month)	Safety and effectiveness not established: NICU or specialist use only	Per specialist	All neonates and infants, including infants with CKD from 1 month: single-dose (benzyl alcohol-free) vials only; never mix with bacteriostatic saline

Preparation & Administration

Handling: do not shake or use a shaken or frozen vial; protect from light; inspect for particles
Dilution: do not dilute or mix with other drugs. Epogen and Procrit only: single-dose vial product may be mixed 1:1 in the syringe with bacteriostatic saline at administration (never in pregnancy, lactation, neonates or infants). Retacrit: no exception
Vials: single-dose vials are not re-entered; discard the unused portion. Multiple-dose vials: refrigerate after entry and discard 21 days after first entry
Route: the label recommends IV injection on hemodialysis (Epogen section 2.2). KDIGO leaves the hemodialysis route to patient preference, local practice and cost (PP 3.4.2.1). Subcut is the route for non-dialysis CKD, peritoneal dialysis and transplant (KDIGO PP 3.4.2.2). Expect to need a higher epoetin dose IV than subcut
Before starting: check iron, correct other causes of anemia, and control blood pressure

Contraindications & Precautions

Contraindications

Uncontrolled hypertension
Pure red cell aplasia (PRCA) that began after epoetin alfa or any other erythropoietin protein drug
Serious allergic reaction to epoetin alfa
Multiple-dose vials (benzyl alcohol) in neonates, infants, pregnant women and lactating women

Precautions

Cardiovascular disease or prior stroke: The risk of death, MI, stroke and thrombosis is higher. Use the lowest dose
Higher Hb targets (CKD): The label says ESAs aimed above 11 g/dL increased death, serious cardiovascular reactions and stroke, and no safe target has been identified (FDA label, Warnings 5.1). KDIGO 2026 targets below 11.5 g/dL (Rec 3.3.1). Use the lowest dose that avoids transfusion
Active or prior cancer: In cancer it can backfire. Survival can shorten, or the tumor can progress (breast, non-small cell lung, head and neck, lymphoid, cervical). Tell the patient before treatment. RBC transfusion is the alternative (ASCO/ASH 2019)
Surgery: more DVT after orthopedic procedures; excess deaths after CABG
Seizures (all patients with CKD): ESAs raise seizure risk. Watch for premonitory neurologic symptoms in the first several months
Hemodialysis: circuit heparin may need to increase
Albumin-containing products (Epogen, Procrit): The risk of viral or CJD transmission is extremely remote

Hold / Reassess If

Hb rise >1 g/dL in 2–4 weeks after starting (CKD): reduce the dose 25–50% (KDIGO Practice Point 3.4.1.2). Differs from FDA label: reduce 25% or more for a rise over 1 g/dL in any 2 weeks. One excursion may not need a change. Avoid dose changes more often than every 4 weeks
Hb approaching 11.5 g/dL (KDIGO Rec 3.3.1: target below 11.5 g/dL): reduce or interrupt. Differs from FDA label: hold at 11 g/dL on dialysis, 10 g/dL not on dialysis; children with CKD: 12 g/dL. To avoid a rapid fall, reduce rather than hold while Hb stays below 11.5 (KDIGO Practice Point 3.4.3.2)
HIV (zidovudine): withhold if Hb >12 g/dL; resume 25% lower when Hb <11 g/dL
Chemotherapy anemia: Hb at the level that avoids transfusion: reduce 25%; above it: withhold, then restart 25% lower when transfusion may again be needed
Blood pressure difficult to control: reduce or withhold
Admission for acute stroke, vascular access thrombosis or VTE: consider suspending (KDIGO)
Severe anemia with a low reticulocyte count: withhold and evaluate for PRCA
Anaphylaxis or a blistering rash: stop permanently

FDA Boxed Warning: ESAs raise the risk of death, MI, stroke, VTE, vascular access thrombosis and tumor progression. In CKD, aiming above 11 g/dL raised those risks, and no safe target has been identified. Use the lowest dose that reduces transfusions. In cancer, reserve it for chemotherapy-induced anemia when cure is not expected, and stop when the course ends. For surgery, give DVT prophylaxis.

Adverse Effects & Toxicity

Common

Hypertension: 28% vs 13% with placebo on dialysis; about 25% need new or more antihypertensives
Arthralgia (12–16%), muscle spasm, fever, dizziness
Dialyzer clotting and vascular access thrombosis: each 8% vs 2–4% with placebo
Chemotherapy: nausea (35%), vomiting (20%), myalgia, bone pain, rash
Zidovudine-treated HIV: fever (42%), cough, rash, injection-site irritation
Surgery: DVT, injection-site pain, pruritus, headache

Serious / Life-Threatening

Effect	Recognition	Management
MI, stroke, death	Chest pain, new neuro deficit; risk highest with high Hb targets or a fast Hb rise	Treat the event; consider suspending the ESA; review Hb target and dose
Venous and access thrombosis	Unilateral leg swelling, dyspnea, pleuritic pain, lost thrill or bruit, clotted dialyzer	Image and anticoagulate; consider suspending the ESA
Hypertensive encephalopathy and seizures	Severe BP rise, headache, confusion, visual change, seizure; mainly CKD, early in therapy	Hold the ESA, control BP, treat seizures
Pure red cell aplasia	Sudden severe anemia, very low reticulocyte count, often after subcut use in CKD	Withhold; test for anti-erythropoietin antibodies; stop permanently if confirmed; never switch to another ESA; transfuse as needed; hematology referral. KDIGO 2026 allows a HIF-PHI later (Practice Point 3.7.6)
Anaphylaxis and angioedema	Urticaria, bronchospasm, hypotension, airway swelling	Stop permanently; treat anaphylaxis (epinephrine IM)
Severe cutaneous reactions	Blistering, skin peeling, mucosal lesions (erythema multiforme, Stevens-Johnson syndrome or toxic epidermal necrolysis)	Stop immediately and permanently; burn or dermatology care

Overdose & Toxicity Management

Signs: Hb above the intended level. Severe hypertension has been reported after an ESA overdose
Management: stop or reduce the dose; phlebotomy when indicated; treat hypertension and thrombotic complications
Antidote: none

Monitoring

Parameter	When / How Often	Target / Act If
Laboratory: Hb	Label: weekly after starting and each dose change until stable, then monthly (KDIGO: every 2–4 weeks after a change)	Act on the Hold / Reassess If list (Hb rise and 11.5 g/dL rules). Hb: hemoglobin
Laboratory: ferritin and TSAT	Before starting and during therapy (KDIGO: every 1–3 months on hemodialysis; every 3 months not on dialysis or on peritoneal dialysis)	KDIGO 2026, not on dialysis (including peritoneal): oral or IV iron if ferritin <100 ng/mL with TSAT <40%, or ferritin 100–299 ng/mL with TSAT <25%. Hemodialysis: IV iron if ferritin ≤500 ng/mL and TSAT ≤30%. All CKD: withhold routine iron if ferritin >700 ng/mL or TSAT ≥40%. Differs from FDA label: iron if ferritin <100 mcg/L or TSAT <20%
Laboratory: reticulocyte count	Baseline; whenever Hb falls unexpectedly	Severe anemia with low reticulocytes: withhold, evaluate for PRCA
Laboratory: other causes of anemia	Before starting; with poor response	Check B12, folate, bleeding, infection, inflammation, dialysis adequacy (CBC)
Clinical: blood pressure	Every dialysis session or visit; each shift when admitted	Hard to control: reduce or withhold the ESA and adjust antihypertensives
Clinical: neuro, thrombosis and access	Every assessment; access thrill and bruit each dialysis session	Headache, confusion or seizure: check BP, hold the ESA. Leg swelling, chest pain, neuro deficit or access clotting: evaluate urgently; consider suspending the ESA
Clinical: response review	Chemotherapy: 8 weeks. CKD: 12-week escalation limit	No response: stop (chemotherapy) or stop escalating and search for causes (CKD)

Interactions & Compatibility

Clinically Significant Interactions

Drug / Class	Effect	What To Do
HIF-PHIs (e.g., vadadustat in the US; daprodustat and roxadustat elsewhere)	No safety or efficacy data for combined use	Do not combine with an ESA (KDIGO 2026 Practice Point 3.5.1)
Other ESAs (darbepoetin alfa, methoxy polyethylene glycol-epoetin beta)	Duplicate therapy; different units and intervals	Never overlap; switch only by nephrology or pharmacy protocol. After PRCA, avoid every ESA
Iron (IV or oral)	Iron deficiency blunts response; iron improves Hb response and lowers ESA dose	Replete iron before and during therapy
Antihypertensives	ESA therapy raises BP: about 25% of dialysis patients needed new or more antihypertensives in trials	Expect to start or increase antihypertensives; check BP each visit
Heparin (hemodialysis circuit)	Artificial kidney clotting more frequent (8% vs 4% with placebo)	Circuit heparin may need to increase; follow the dialysis protocol

IV Compatibility

Diluents: none; give undiluted (admixture rules under Dosing)
Line: IV injection or subcut; no infusion
Verify with an institutional compatibility resource.

Special Populations

Pediatrics: Labeled for CKD from 1 month of age and for chemotherapy anemia from 5 to 18 years. Safety resembles adults. KDIGO says individualize the Hb target. A higher threshold to start may suit children and transplant candidates. See the Pediatric Dosing table and weight-based dosing.
Neonates: Single-dose vials only, because benzyl alcohol causes fatal gasping syndrome. Epoetin is not a neuroprotectant. In the HEAL trial, 1,000 units/kg IV ×5 doses with cooling for hypoxic-ischemic encephalopathy did not reduce death or disability. It caused more serious adverse events.
Pregnancy: Human data are too limited to define the risk. Animal studies at clinical doses showed fetal harm. Polyhydramnios and growth restriction have been reported in women with CKD, though the disease muddies the picture. If it is needed, use a single-dose vial only, never bacteriostatic saline.
Lactation: There are no data on transfer into milk. Use single-dose vials with caution. After a multiple-dose vial, avoid breastfeeding for at least 2 weeks.
Older Adults: Trials showed no overall difference in safety or effectiveness. Individualize the dose to the Hb target.
Renal Impairment: CKD is the main indication. There is no renal dose adjustment beyond Hb-guided titration. Half-life is similar on and off dialysis. On hemodialysis, you may need more circuit heparin.
Hepatic Impairment: no specific adjustment established.
Obesity / Dosing Weight: Labeled doses are per kg of body weight. Titrate to Hb.
Cancer with CKD: Weigh the benefit against tumor risk. That matters most when cancer treatment aims at cure.
Critically Ill Patients: Inflammation blunts the response. Routine use for ICU anemia does not reduce transfusions, and it adds thrombosis.

Clinical Pearls

Exam Discriminator, Poor Response: Poor response? Work the causes first: iron deficiency, infection or inflammation, blood loss and inadequate dialysis. Severe anemia with a near-zero reticulocyte count points to antibody-mediated PRCA.

PRCA Means No ESA: Neutralizing antibodies cause it. PRCA after any erythropoietin product rules out every ESA. Stop permanently. Do not switch to darbepoetin or another ESA. Transfuse as needed and involve hematology.

Admitted With a Clot: Stroke, access thrombosis or VTE on admission? Ask whether the ESA should be held for the admission. Restarting is a shared decision with nephrology or oncology.

Not a Rescue Drug: Reticulocytes take up to 10 days to rise. Hb takes weeks. Bleeding or symptomatic acute anemia? Transfuse. A new headache, confusion or seizure after a recent ESA start needs a blood pressure check for hypertensive encephalopathy.

Pharmacology

Mechanism of Action

Recombinant human erythropoietin. Its 165-amino-acid sequence matches the hormone the renal cortex makes.
It binds erythropoietin receptors on marrow erythroid progenitors. Their survival and maturation go up, and reticulocytosis and red cell mass follow.
CKD anemia is driven largely by erythropoietin deficiency. Replacement works if iron and other substrates are adequate.

Pharmacokinetics

Route	Onset	Peak	Duration
IV	Reticulocytes rise within 10 days; Hb rise in 2–6 weeks	Plasma: end of injection	Plasma half-life 4–13 hr (CKD)
Subcut	Reticulocytes rise within 10 days; Hb rise in 2–6 weeks	Plasma: 5–24 hr	Plasma half-life about 40 hr (16–67 hr) in cancer patients

Half-life: IV 4–13 hr in adults and children with CKD; similar with creatinine >3 mg/dL on or off dialysis; not affected by age over 65
Metabolism: a glycoprotein; no CYP450 metabolism and no CYP interactions

Names & Classification

Generic Name: Epoetin alfa (recombinant human erythropoietin); biosimilar epoetin alfa-epbx
Brand Names: Epogen (Amgen), Procrit (Janssen), Retacrit (epoetin alfa-epbx, Pfizer); Eprex outside the US
Pharmacologic Class: Erythropoiesis-stimulating agent (ESA); recombinant erythropoietin
Therapeutic Class: Antianemic (hematopoietic agent)
Controlled Substance: Not controlled
ISMP High-Alert: No
Look-Alike / Sound-Alike: Epoetin alfa / darbepoetin alfa (units vs mcg, different intervals); single-dose vs multiple-dose vials (benzyl alcohol)
Error-Prone Abbreviations to Avoid: “U” or “IU” for units (misread as 0, 4 or IV)

References

Amgen Inc. (2024). Epogen (epoetin alfa) injection: Prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5
Pfizer Laboratories. (2024). Retacrit (epoetin alfa-epbx) injection: Prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3af26b0d-8ad0-44e1-a538-8bdb5ab39374
Janssen Products, LP. (2024). Procrit (epoetin alfa) injection: Prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c721ba4-ae19-417f-aae1-221ed1a0866a
Babitt, J. L., Berns, J. S., Bozkurt, B., et al. (2026). Executive summary of the KDIGO 2026 clinical practice guideline for the management of anemia in chronic kidney disease (CKD). Kidney International, 109(1), 44–56. https://doi.org/10.1016/j.kint.2025.06.005
KDIGO Anemia in CKD Work Group. (2026). KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD). Kidney International, 109(1S), S1–S99. https://kdigo.org/wp-content/uploads/2026/04/KDIGO-2026-Anemia-in-CKD-Guideline.pdf
Bohlius, J., Bohlke, K., Castelli, R., et al. (2019). Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Journal of Clinical Oncology, 37(15), 1336–1351. https://doi.org/10.1200/JCO.18.02142
Vest, L. S., Patel, P., & Patel, J. B. (2024). Epoetin alfa. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK554547/
Wu, Y. W., Comstock, B. A., Gonzalez, F. F., et al. (2022). Trial of erythropoietin for hypoxic-ischemic encephalopathy in newborns. New England Journal of Medicine, 387(2), 148–159. https://doi.org/10.1056/NEJMoa2119660
Corwin, H. L., Gettinger, A., Fabian, T. C., et al. (2007). Efficacy and safety of epoetin alfa in critically ill patients. New England Journal of Medicine, 357(10), 965–976. https://doi.org/10.1056/NEJMoa071533

Last updated October 2026 Spotted something wrong? Report an error and include the page URL.

Medical Disclaimer

For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.

AI Assistance Notice

AI was used to assist in organizing, paraphrasing, and formatting this information.